Process of making somatostatin modulators
Inventors
REDDY, Jayachandra P. • Mirmehrabi, Mahmoud
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
Core Innovation
The patent disclosure describes crystalline 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, also designated Compound A mono-HCl, or a solvate thereof, characterized by XRPD, DSC, and IR spectral properties. The text reports SSTR2 agonist and modulator activity for the compound, alongside comparisons of solubility and moisture uptake among salt forms. It also describes preparation routes and purification for quinoline analogs, reporting improvements in HPLC purity and measures addressing residual palladium.
The independent claim covers orally administering a pharmaceutical composition comprising the crystalline monohydrochloride compound or a solvate thereof and at least one pharmaceutically acceptable excipient to a human with acromegaly, a neuroendocrine tumor, or both. The crystalline compound further exhibits an unchanged XRPD pattern following exposure to heat and humidity. The compound is identified for potential therapeutic use in treating acromegaly and neuroendocrine tumors.
Claims Coverage
The claims identify one independent claim directed to oral treatment using a pharmaceutical composition containing the specified crystalline monohydrochloride compound or a solvate thereof, comprising two inventive features.
Oral treatment of acromegaly or a neuroendocrine tumor
The claim covers orally administering to a human with acromegaly, a neuroendocrine tumor, or both, a pharmaceutical composition comprising the specified crystalline monohydrochloride compound or a solvate thereof and at least one pharmaceutically acceptable excipient, with dependent claims specifying amounts of 1-100 mg, once-daily administration, and tablet or capsule forms.
Characterized crystalline form of the monohydrochloride compound
The crystalline compound is characterized by an XRPD pattern with peaks at 4.5°, 9.1°, 10.2°, 16.3°, 18.4°, and 19.1° 2-Theta; a DSC endotherm with an onset at about 207°C and a peak at about 220°C; and IR peaks at 2223, 1620, 1595, 1457, 1238, 1220, and 1117 cm⁻¹, with an unchanged XRPD pattern after heat or humidity exposure.
The independent claim combines oral treatment of acromegaly, a neuroendocrine tumor, or both in a human with a pharmaceutical composition containing the crystalline monohydrochloride form defined by XRPD, DSC, and IR parameters and stability under heat or humidity exposure.
Stated Advantages
The crystalline monohydrochloride salt remains crystalline after heating to 200°C and maintains an unchanged XRPD pattern under heat and high-humidity exposure.
The monohydrochloride salt shows lower reversible moisture uptake than the dihydrochloride salt.
Documented Applications
Oral treatment in humans of acromegaly, a neuroendocrine tumor, or both, using a pharmaceutical composition containing the crystalline monohydrochloride compound or a solvate thereof.
Interested in licensing this patent?